Adjuvant HIPEC to Prevent Colorectal Peritoneal Metastases in High-risk Patients
Status:
Completed
Trial end date:
2011-12-01
Target enrollment:
Participant gender:
Summary
The prognosis of peritoneal metastases from colorectal cancer has recently improved with
cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC). Although
outcomes are further improved when early stage peritoneal metastases are treated, adjuvant
HIPEC has not yet been thoroughly addressed. This prospective pilot study assessed
feasibility, safety and efficacy of HIPEC performed simultaneously with primary curative
surgery in colorectal cancer patients with primary tumor-related risk-factors for the
development of metachronous peritoneal metastases.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano